InspireMD Shows Stable Capital Structure in Q2 2025 Filing
Ticker: NSPR · Form: 10-Q · Filed: Aug 4, 2025 · CIK: 1433607
| Field | Detail |
|---|---|
| Company | Inspiremd, INC. (NSPR) |
| Form Type | 10-Q |
| Filed Date | Aug 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: Medical Devices, 10-Q Filing, Capital Structure, SEC Filing, Biotech, Healthcare, Quarterly Report
Related Tickers: NSPR
TL;DR
**NSPR's Q2 filing shows a flat capital structure, signaling a holding pattern rather than aggressive growth or distress.**
AI Summary
InspireMD, Inc. filed its 10-Q for the period ending June 30, 2025, indicating a continued focus on its medical device operations. The company's financial statements show a consistent structure in its capital accounts, with no significant changes in Series C Preferred Stock or Common Stock outstanding between December 31, 2024, and June 30, 2025. Additional Paid-In Capital and Retained Earnings also remained stable across these periods, suggesting no major equity financing or dividend distributions. The filing covers the second quarter of 2025 (April 1 to June 30, 2025) and the first six months of 2025 (January 1 to June 30, 2025), with comparative data for the same periods in 2024. While specific revenue and net income figures are not explicitly detailed in the provided excerpt, the stability in capital accounts implies a period of operational consistency rather than rapid expansion or contraction. The company's strategic outlook likely remains centered on its surgical and medical instruments apparatus, as indicated by its SIC code 3841.
Why It Matters
For investors, the stable capital structure suggests InspireMD is not undergoing immediate dilutive financing or significant capital restructuring, which can be a double-edged sword – stability but also potentially a lack of aggressive growth initiatives. Employees might see this as a period of consistent operations, while customers can expect continued product availability from a company focused on its core medical device offerings. In the competitive medical instruments market, this stability could indicate InspireMD is holding its ground against larger players, but without revenue or net income details, it's hard to assess its competitive momentum.
Risk Assessment
Risk Level: medium — The risk level is medium because while the capital structure appears stable with no immediate signs of distress or significant dilution, the absence of specific revenue and net income figures in the provided excerpt prevents a full assessment of operational performance and profitability. This lack of detailed financial performance data makes it difficult to gauge the company's ability to generate cash flow and sustain operations, which is a key risk for investors.
Analyst Insight
Investors should seek out the full 10-Q to analyze revenue growth, net income, and cash flow statements to understand InspireMD's operational performance. Without these critical metrics, any investment decision would be speculative, as the stable capital structure alone doesn't guarantee business health.
Key Numbers
- 0001433607 — Central Index Key (CIK) (Unique identifier for InspireMD, Inc. with the SEC.)
- 3841 — Standard Industrial Classification (SIC) (Indicates the company operates in Surgical & Medical Instruments & Apparatus.)
- 2025-06-30 — Conformed Period of Report (The end date of the financial period covered by this 10-Q filing.)
- 2025-08-04 — Filed As Of Date (The date the 10-Q was officially filed with the SEC.)
Key Players & Entities
- InspireMD, Inc. (company) — filer of the 10-Q
- SEC (regulator) — recipient of the 10-Q filing
- Bloomberg (company) — publisher of this analysis
- Saguaro Resources, Inc. (company) — former name of InspireMD, Inc.
- December 31, 2024 (date) — balance sheet comparison date
- June 30, 2025 (date) — current period end date for the 10-Q
- April 1, 2025 (date) — start of current quarter
- January 1, 2025 (date) — start of current six-month period
FAQ
What is InspireMD, Inc.'s primary business according to its 10-Q filing?
InspireMD, Inc.'s primary business is categorized under Standard Industrial Classification (SIC) code 3841, which corresponds to Surgical & Medical Instruments & Apparatus. This indicates their focus on developing and manufacturing medical devices.
When was InspireMD, Inc.'s 10-Q for Q2 2025 filed?
InspireMD, Inc.'s 10-Q for the period ending June 30, 2025, was filed with the SEC on August 4, 2025, as indicated by the 'Filed As Of Date' in the filing header.
Did InspireMD, Inc. issue new common stock or preferred stock in Q2 2025?
Based on the provided excerpt, there were no changes in the amounts of Common Stock or Series C Preferred Stock between December 31, 2024, and June 30, 2025, suggesting no new issuances during this period.
What does the stability in Additional Paid-In Capital mean for InspireMD, Inc.?
The stability in Additional Paid-In Capital from December 31, 2024, to June 30, 2025, suggests that InspireMD, Inc. did not raise significant equity capital through stock offerings during this period, nor did it engage in major share repurchases affecting this account.
How does InspireMD, Inc.'s capital structure compare between 2024 and 2025 in the 10-Q?
The 10-Q provides comparative data for capital accounts, showing consistent figures for Common Stock, Series C Preferred Stock, Additional Paid-In Capital, and Retained Earnings between December 31, 2024, and June 30, 2025, as well as for the corresponding periods in 2024.
What is the fiscal year end for InspireMD, Inc.?
InspireMD, Inc.'s fiscal year ends on December 31, as stated in the 'FISCAL YEAR END' field of the company data.
Where is InspireMD, Inc.'s business address located?
InspireMD, Inc.'s business address is 6303 Waterford District Drive, Suite 215, Miami, FL 33126, as detailed in the business address section of the filing.
What was InspireMD, Inc.'s former company name?
InspireMD, Inc.'s former company name was Saguaro Resources, Inc., with the name change occurring on April 28, 2008.
Does the 10-Q provide details on InspireMD, Inc.'s revenue for Q2 2025?
The provided excerpt of the 10-Q filing does not explicitly detail specific revenue figures for Q2 2025 or the first six months of 2025, focusing instead on capital account balances.
What is the significance of the 'Conformed Period of Report' for InspireMD, Inc.'s 10-Q?
The 'Conformed Period of Report' of 20250630 signifies that the financial information presented in this 10-Q covers the company's performance and financial position up to June 30, 2025, for the second quarter and first half of the year.
Industry Context
InspireMD, Inc. operates within the Surgical & Medical Instruments & Apparatus industry (SIC 3841). This sector is characterized by innovation, stringent regulatory oversight, and competition from both large established players and smaller specialized firms. Trends include the development of minimally invasive surgical tools and advanced diagnostic equipment.
Regulatory Implications
As a medical device company, InspireMD is subject to rigorous regulatory scrutiny from bodies like the FDA. Compliance with manufacturing standards, product approvals, and post-market surveillance are critical. Any delays in regulatory processes or adverse findings can significantly impact operations and market access.
What Investors Should Do
- Monitor revenue and profitability trends in future filings.
- Investigate any potential future equity financing or debt changes.
- Track regulatory news and product development updates.
Key Dates
- 2025-06-30: Conformed Period of Report — Marks the end of the second quarter and the first six months of fiscal year 2025 for this 10-Q filing.
- 2025-08-04: Filed As Of Date — The date InspireMD, Inc. officially submitted its 10-Q filing to the SEC.
- 2025-04-01: Start of Q2 2025 — Beginning of the second fiscal quarter for which financial results are reported in this 10-Q.
- 2024-04-01: Start of Q2 2024 — Beginning of the second fiscal quarter for comparative financial data in this 10-Q.
- 2024-01-01: Start of Q1 2024 — Beginning of the first fiscal quarter for comparative financial data in this 10-Q.
- 2024-12-31: End of Fiscal Year 2024 — Represents the end of the prior fiscal year, used for balance sheet comparisons in the 10-Q.
Glossary
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the primary source of financial information for InspireMD, Inc. for the specified quarter.)
- Series C Preferred Stock
- A class of preferred stock, often issued with specific rights and preferences, that is distinct from common stock. (The stability of this account suggests no new issuances or redemptions of this preferred stock during the reporting period.)
- Additional Paid-In Capital
- The amount of capital a company has received from shareholders in exchange for stock, exceeding the par value of the stock. (Its stability indicates no significant stock issuance activities beyond normal operations or employee stock plans.)
- Retained Earnings
- The cumulative amount of net income that a company has retained over time, rather than distributing to shareholders as dividends. (The stability suggests no significant net income generation or dividend payouts during the period.)
- SIC Code 3841
- Standard Industrial Classification code for 'Surgical & Medical Instruments & Apparatus', indicating the company's primary industry. (Confirms InspireMD's focus on the medical device sector, specifically in surgical and medical instruments.)
Year-Over-Year Comparison
The provided excerpt for the 10-Q ending June 30, 2025, indicates stability in key balance sheet components like Series C Preferred Stock, Common Stock, Additional Paid-In Capital, and Retained Earnings when compared to December 31, 2024. This suggests a lack of significant equity financing or dividend activity. Without comparative income statement data for the prior year's periods (Q2 2024 vs. Q2 2025, and YTD 2024 vs. YTD 2025), a direct comparison of revenue growth, margin changes, or profitability is not possible from this excerpt.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 4, 2025 regarding InspireMD, Inc. (NSPR).